(Stroke. 1997;28:708-710.)
© 1997 American Heart Association, Inc.
Articles |
Duration of Glutamate Release After Acute Ischemic Stroke
From the Section of Neurology, Hospital Universitari Doctor Josep Trueta, Girona (A.D., J.S.), and Department of Neurology, Hospital General de Galicia, Clínico Universitario, Santiago de Compostela (J.C., M.N.), Spain.
Correspondence to Antoni Dávalos, MD, Section of Neurology, Hospital Universitari Doctor Josep Trueta, 17007 Girona, Spain. E-mail adavalose{at}meditex.es
Background and Purpose High levels of glutamate in plasma and cerebrospinal fluid (CSF) have been demonstrated in patients with acute ischemic stroke. The duration of this excitatory amino acid release has not been studied, and therefore the window of opportunity of treatment with glutamate antagonists is unknown. The aim of this investigation was to study the duration of the glutamate increase in patients with stable and progressing ischemic stroke.
Methods Glutamate in CSF was measured by high-performance liquid chromatography in 184 patients with an acute cerebral infarction of less than 24 hours' duration and in 43 control subjects.
Results Among the 120 patients with stable ischemic stroke, median glutamate levels were significantly lower—and within the reference range of control subjects—in those patients studied 6 to 24 hours from onset of symptoms than in patients studied in the first 6 hours (3 [range, 2 to 10] versus 5 µmol/L [range, 2 to 17]; P<.0001). In 64 patients with progressing ischemic stroke, glutamate concentrations measured at any time interval during the first 24 hours from onset were significantly higher than in the stable stroke and control groups.
Conclusions The presence of glutamate increase in the CSF cannot be documented for greater than 6 hours in stable ischemic stroke. The sustained elevation of glutamate observed in progressing stroke suggests that the window to prevent neurological deterioration may be wider.
Key Words: excitotoxicity • stroke outcome • neuroprotection • glutamate
This article has been cited by other articles:
 |
|
 |
|
  J. A. Alawneh, R. R. Moustafa, and J.-C. Baron Hemodynamic Factors and Perfusion Abnormalities in Early Neurological Deterioration Stroke, June 1, 2009; 40(6): e443 - e450. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. A. Donnan and S. M. Davis Neuroprotection: Still Achievable in Humans Stroke, February 1, 2008; 39(2): 525 - 525. [Full Text] [PDF]
|
|
|
|
 |
|
 R. Yaka, A. Biegon, N. Grigoriadis, C. Simeonidou, S. Grigoriadis, A. G. Alexandrovich, H. Matzner, J. Schumann, V. Trembovler, J. Tsenter, et al. D-cycloserine improves functional recovery and reinstates long-term potentiation (LTP) in a mouse model of closed head injury FASEB J, July 1, 2007; 21(9): 2033 - 2041. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Mallolas, O. Hurtado, M. Castellanos, M. Blanco, T. Sobrino, J. Serena, J. Vivancos, J. Castillo, I. Lizasoain, M. A. Moro, et al. A polymorphism in the EAAT2 promoter is associated with higher glutamate concentrations and higher frequency of progressing stroke J. Exp. Med., March 20, 2006; 203(3): 711 - 717. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Biegon, P. A. Fry, C. M. Paden, A. Alexandrovich, J. Tsenter, and E. Shohami Dynamic changes in N-methyl-D-aspartate receptors after closed head injury in mice: Implications for treatment of neurological and cognitive deficits PNAS, April 6, 2004; 101(14): 5117 - 5122. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Fisher Recommendations for Advancing Development of Acute Stroke Therapies: Stroke Therapy Academic Industry Roundtable 3 Stroke, June 1, 2003; 34(6): 1539 - 1546. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. F. Arenillas, A. Rovira, C. A. Molina, E. Grive, J. Montaner, J. Alvarez-Sabin, and K.-O. Lovblad Prediction of Early Neurological Deterioration Using Diffusion- and Perfusion-Weighted Imaging in Hyperacute Middle Cerebral Artery Ischemic Stroke * Editorial Comment Stroke, September 1, 2002; 33(9): 2197 - 2205. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Gilgun-Sherki, Z. Rosenbaum, E. Melamed, and D. Offen Antioxidant Therapy in Acute Central Nervous System Injury: Current State Pharmacol. Rev., June 1, 2002; 54(2): 271 - 284. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. A. Sun, S. Sombati, and R. J. DeLorenzo Glutamate Injury-Induced Epileptogenesis in Hippocampal Neurons: An In Vitro Model of Stroke-Induced "Epilepsy" Stroke, October 1, 2001; 32(10): 2344 - 2350. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Serena, R. Leira, J. Castillo, J. M. Pumar, M. Castellanos, and A. Davalos Neurological Deterioration in Acute Lacunar Infarctions : The Role of Excitatory and Inhibitory Neurotransmitters Stroke, May 1, 2001; 32(5): 1154 - 1161. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. J. Traystman, J. A. Klaus, A. C. DeVries, A. B. Shaivitz, and P. D. Hurn Anticonvulsant Lamotrigine Administered on Reperfusion Fails To Improve Experimental Stroke Outcomes Stroke, March 1, 2001; 32(3): 783 - 787. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Tei, S. Uchiyama, K. Ohara, M. Kobayashi, Y. Uchiyama, and M. Fukuzawa Deteriorating Ischemic Stroke in 4 Clinical Categories Classified by the Oxfordshire Community Stroke Project Stroke, September 1, 2000; 31(9): 2049 - 2054. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Davalos, J. Castillo, J. Marrugat, J. M. Fernandez-Real, A. Armengou, P. Cacabelos, and R. Rama Body iron stores and early neurologic deterioration in acute cerebral infarction Neurology, April 25, 2000; 54(8): 1568 - 1574. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Castillo, R. Rama, and A. Davalos Nitric Oxide-Related Brain Damage in Acute Ischemic Stroke Stroke, April 1, 2000; 31(4): 852 - 857. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Davalos, D. Toni, F. Iweins, E. Lesaffre, S. Bastianello, and J. Castillo Neurological Deterioration in Acute Ischemic Stroke : Potential Predictors and Associated Factors in the European Cooperative Acute Stroke Study (ECASS) I Stroke, December 1, 1999; 30(12): 2631 - 2636. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Turski, A. Huth, M. Sheardown, F. McDonald, R. Neuhaus, H. H. Schneider, U. Dirnagl, F. Wiegand, P. Jacobsen, and E. Ottow ZK200775: A phosphonate quinoxalinedione AMPA antagonist for neuroprotection in stroke and trauma PNAS, September 1, 1998; 95(18): 10960 - 10965. [Abstract] [Full Text] [PDF]
|
|